1232860-68-2Relevant academic research and scientific papers
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma
Itadani, Satoshi,Yashiro, Kentaro,Aratani, Yoshiyuki,Sekiguchi, Tetsuya,Kinoshita, Atsushi,Moriguchi, Hideki,Ohta, Nobukazu,Takahashi, Shinya,Ishida, Akiharu,Tajima, Yohei,Hisaichi, Katsuya,Ima, Masaki,Ueda, Junya,Egashira, Hiromu,Sekioka, Tomohiko,Kadode, Michiaki,Yonetomi, Yasuo,Nakao, Takafumi,Inoue, Atsuto,Nomura, Hiroaki,Kitamine, Tetsuya,Fujita, Manabu,Nabe, Takeshi,Yamaura, Yoshiyuki,Matsumura, Naoya,Imagawa, Akira,Nakayama, Yoshisuke,Takeuchi, Jun,Ohmoto, Kazuyuki
, p. 6093 - 6113 (2015/08/24)
An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole
CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID
-
, (2013/04/13)
The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.
ETHYNYLINDOLE COMPOUNDS
-
Page/Page column 10-11, (2010/07/04)
As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 /sub
